Top Ad

Aceclofenac + Paracetamol tablets

Form: Tablets

Strength: 100 mg Aceclofenac + 325 mg Paracetamol

Reference Brands: Generic formulations marketed under different names

Category: Analgesic

Aceclofenac + Paracetamol combination is approved in the EU for pain and inflammation, regulated by EMA with dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, such combinations are generally not approved, and regulatory approval is pending or unavailable. In Europe, generic formulations are marketed under various brands, adhering to strict standards. Both regions require detailed dossiers, clinical data, and pharmacovigilance for approval. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for aceclofenac + paracetamol, ensuring adherence to European standards for safe, effective analgesic therapy, navigating complex regulations seamlessly.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Dexketoprofen + Tramadol tablets

Strength: 25 mg dexketoprofen + 37.5 mg tramadol

Form: Tablets

Reference Brands: Enantyum(EU)

View More Get Enquiry
Paracetamol + Codeine tablets

Strength: 300 mg paracetamol + 30 mg codeine; 300 mg + 60 mg

Form: Tablets

Reference Brands: Tylenol with Codeine(US)

View More Get Enquiry
Tramadol + Paracetamol tablets

Strength: 37.5 mg tramadol + 325 mg paracetamol; 75 mg + 650 mg

Form: Oral Tablets

Reference Brands: Ultracet(US); Tramacet(EU)

View More Get Enquiry
Prilocaine + Lidocaine Creams and Ointments

Strength: 2.5%, 5%, 7% (prilocaine); 2.5% lidocaine

Form: Creams and Ointments

Reference Brands: EMLA, Oraqix, Ametop(US & EU)

View More Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.